Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Genome-wide increase in histone H2A ubiquitylation in a mouse model of Huntington's disease.

McFarland KN, Das S, Sun TT, Leyfer D, Kim MO, Xia E, Sangrey GR, Kuhn A, Luthi-Carter R, Clark TW, Sadri-Vakili G, Cha JH.

J Huntingtons Dis. 2013;2(3):263-77. doi: 10.3233/JHD-130066.

PMID:
25062675
2.

Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease.

McFarland KN, Das S, Sun TT, Leyfer D, Xia E, Sangrey GR, Kuhn A, Luthi-Carter R, Clark TW, Sadri-Vakili G, Cha JH.

PLoS One. 2012;7(7):e41423. doi: 10.1371/journal.pone.0041423. Epub 2012 Jul 27.

3.

The polyubiquitin Ubc gene modulates histone H2A monoubiquitylation in the R6/2 mouse model of Huntington's disease.

Bett JS, Benn CL, Ryu KY, Kopito RR, Bates GP.

J Cell Mol Med. 2009 Aug;13(8B):2645-57. doi: 10.1111/j.1582-4934.2008.00543.x.

4.

Altered histone monoubiquitylation mediated by mutant huntingtin induces transcriptional dysregulation.

Kim MO, Chawla P, Overland RP, Xia E, Sadri-Vakili G, Cha JH.

J Neurosci. 2008 Apr 9;28(15):3947-57. doi: 10.1523/JNEUROSCI.5667-07.2008.

5.

Neuronal identity genes regulated by super-enhancers are preferentially down-regulated in the striatum of Huntington's disease mice.

Achour M, Le Gras S, Keime C, Parmentier F, Lejeune FX, Boutillier AL, Néri C, Davidson I, Merienne K.

Hum Mol Genet. 2015 Jun 15;24(12):3481-96. doi: 10.1093/hmg/ddv099. Epub 2015 Mar 17.

PMID:
25784504
6.

Genome-wide uH2A localization analysis highlights Bmi1-dependent deposition of the mark at repressed genes.

Kallin EM, Cao R, Jothi R, Xia K, Cui K, Zhao K, Zhang Y.

PLoS Genet. 2009 Jun;5(6):e1000506. doi: 10.1371/journal.pgen.1000506. Epub 2009 Jun 5.

7.

Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models.

Sadri-Vakili G, Bouzou B, Benn CL, Kim MO, Chawla P, Overland RP, Glajch KE, Xia E, Qiu Z, Hersch SM, Clark TW, Yohrling GJ, Cha JH.

Hum Mol Genet. 2007 Jun 1;16(11):1293-306. Epub 2007 Apr 4.

PMID:
17409194
8.

Specific promoter deacetylation of histone H3 is conserved across mouse models of Huntington's disease in the absence of bulk changes.

Guiretti D, Sempere A, Lopez-Atalaya JP, Ferrer-Montiel A, Barco A, Valor LM.

Neurobiol Dis. 2016 May;89:190-201. doi: 10.1016/j.nbd.2016.02.004. Epub 2016 Feb 3.

PMID:
26851501
9.
10.

The Role of H3K4me3 in Transcriptional Regulation Is Altered in Huntington's Disease.

Dong X, Tsuji J, Labadorf A, Roussos P, Chen JF, Myers RH, Akbarian S, Weng Z.

PLoS One. 2015 Dec 4;10(12):e0144398. doi: 10.1371/journal.pone.0144398. eCollection 2015.

11.

Modulation of nucleosome dynamics in Huntington's disease.

Stack EC, Del Signore SJ, Luthi-Carter R, Soh BY, Goldstein DR, Matson S, Goodrich S, Markey AL, Cormier K, Hagerty SW, Smith K, Ryu H, Ferrante RJ.

Hum Mol Genet. 2007 May 15;16(10):1164-75. Epub 2007 Apr 2.

PMID:
17403718
12.

Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice.

McCaw EA, Hu H, Gomez GT, Hebb AL, Kelly ME, Denovan-Wright EM.

Eur J Biochem. 2004 Dec;271(23-24):4909-20.

13.

Mechanisms of disease: Histone modifications in Huntington's disease.

Sadri-Vakili G, Cha JH.

Nat Clin Pract Neurol. 2006 Jun;2(6):330-8. Review.

PMID:
16932577
14.

ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease.

Ryu H, Lee J, Hagerty SW, Soh BY, McAlpin SE, Cormier KA, Smith KM, Ferrante RJ.

Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19176-81. Epub 2006 Dec 1.

15.

Cerebellar lipid differences between R6/1 transgenic mice and humans with Huntington's disease.

Denny CA, Desplats PA, Thomas EA, Seyfried TN.

J Neurochem. 2010 Nov;115(3):748-58. doi: 10.1111/j.1471-4159.2010.06964.x. Epub 2010 Sep 27.

16.

Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease.

Chen-Plotkin AS, Sadri-Vakili G, Yohrling GJ, Braveman MW, Benn CL, Glajch KE, DiRocco DP, Farrell LA, Krainc D, Gines S, MacDonald ME, Cha JH.

Neurobiol Dis. 2006 May;22(2):233-41. Epub 2006 Jan 24.

PMID:
16442295
18.

Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease.

Desplats PA, Kass KE, Gilmartin T, Stanwood GD, Woodward EL, Head SR, Sutcliffe JG, Thomas EA.

J Neurochem. 2006 Feb;96(3):743-57. Epub 2006 Jan 9.

19.

Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease.

Tang B, Becanovic K, Desplats PA, Spencer B, Hill AM, Connolly C, Masliah E, Leavitt BR, Thomas EA.

Hum Mol Genet. 2012 Jul 15;21(14):3097-111. doi: 10.1093/hmg/dds132. Epub 2012 Apr 6.

20.

Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease.

Xiang Z, Valenza M, Cui L, Leoni V, Jeong HK, Brilli E, Zhang J, Peng Q, Duan W, Reeves SA, Cattaneo E, Krainc D.

J Neurosci. 2011 Jun 29;31(26):9544-53. doi: 10.1523/JNEUROSCI.1291-11.2011.

Supplemental Content

Support Center